[Comparative efficiency and side effects of combined antiviral therapy of chronic hepatitis C].
The study included 100 patients with chronic hepatitis C previously untreated by interferon preparations. Patients of group I (n=53) were given pegylated interferon alpha-2b (PEG IFN) and rebetol, patients of group 2 (n=47) PEG IFN and copegus. The overall efficiency of therapy regardless of hepatitis C virus genotype in the two groups was estimated at 83 and 79% respectively. It was 65% in patients with virus genotype 1b in group 1 and 69% in group 2 In patients with virus genotypes 2 and 3, the efficiency was estimated at 100 and 91% in groups 1 and 2 respectively. The efficiency of therapy depended on the duration of the period during which the virological response was obtained. Side effects in the form of disturbed sleep, musculo-articular pain, and anorexia occurred in group 1 more frequently than in group 2 The reverse was true of scalp reactions and psycho-emotional distress.
Gromova
N I
NI
Bogomolov
B P
BP
D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000998:Antiviral Agents; D004279:DNA, Viral; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a